One hundred seventy-six consecutive patients treated with IV tissue plasminogen activator (tPA) for acute ischemic stroke were examined prospectively, and orolingual angioedema was found in nine (5.1%; 95% CI 2.3 to 9.5). The reaction was typically mild, transient, and contralateral to the ischemic hemisphere. Risk of angioedema was associated with angiotensin-converting enzyme inhibitors (relative risk [RR] 13.6; 95% CI 3.0 to 62.7) and signs on initial CT of ischemia in the insular and frontal cortex (RR 9.1; 95% CI 1.4 to 30.0).
NEUROLOGY 2003;60: [1525] [1526] [1527] Angioedema has been reported in association with IV alteplase use in the treatment of acute ischemic stroke. 1, 2 Angioedema is associated with angiotensinconverting enzyme inhibitor (ACEi) therapy. 3 Epidemiologic evidence suggests that genetic factors such as anomalies of bradykinin metabolism may be implicated. Additionally, clinical and experimental work has shown that the insular cortex has an important role in basal cardiac sympathetic tone. 4, 5 We have previously reported four cases of angioedema and postulated that a three-way interaction among alteplase, stroke, and ACEi use was involved in the generation of angioedema after stroke treatment. 6 We undertook the following investigation to assess the hypothesis that premorbid ACEi use and insular infarction were contributing factors in the development angioedema among tissue plasminogen activator (tPA)-treated ischemic stroke patients.
Methods. The Calgary Stroke Program 7 serves a population of 1.4 million. Consecutive patients treated with alteplase for stroke from 1996 through 2001 were prospectively followed. After the first case of angioedema, all patients were examined at 45, 60, and 75 minutes and 24 hours after alteplase bolus treatment for orolingual angioedema, defined as unprovoked swelling of the tongue, lips, or oropharynx. Medications were prospectively recorded in the medical record. All surviving patients were contacted and provided informed consent for crosscheck of this medication list with their local pharmacy records.
The relative risk (RR) for the development of angioedema according to whether or not the patient was taking an ACEi or one of four other medications (␤-blockers, calcium channel blockers, angiotensin II receptor antagonists, and nonsteroidal antiinflammatory drugs) was determined. The role of the baseline CT scan was assessed by the treating physician using the Alberta Stroke Program Early CT Scale (ASPECTS). 8, 9 ASPECTS is a 10point scale in which each point is a binary score: 0 for signs of early ischemia and 1 for normal. Each point corresponds to a region in the middle cerebral artery territory, combining localization and volume into a semiquantitative topographic score. Only areas of new, acute ischemia are scored. Because ASPECTS gives a topographic score, it was possible to assess the RR for the development of angioedema according to any of the 10 ASPECTS regions.
The regional ethics review board approved the study. Patients provided informed consent for the use and linkage of their medical and pharmacy records. Confidence intervals were determined using exact methods, all statistical tests were two sided, and the conventional threshold for significance, ␣ ϭ 0.05, was used.
Results. Over 5 years, 176 patients were treated with IV alteplase in a single city. The median NIH Stroke Scale score was 15.5 (table 1). A significant proportion of patients were taking ACEi (20%), ␤-blockers (26%), and calcium channel blockers (19%), and fewer were taking angiotensin II receptor antagonists (8%) or nonsteroidal anti-inflammatory agents (7%). When stratifying patients according to whether or not they were taking an ACEi, there was no difference in the frequency of use of any of the other target medications.
Pharmacy records confirmed the prospectively gathered medication list in 39% of surviving patients. Most pharmacies in the region did not keep records dating back further than 2 years. Changes or additions were made in only 13 of 277 (4.7%) target medications.
Nine patients (5.1%; 95% CI 2.3 to 9.5) developed orolingual angioedema. In eight cases, the swelling began hemilingually, and in one case, laterality at onset was not noted. In seven of eight cases, the onset was contralateral to the ischemic hemisphere. Six of these patients had middle cerebral artery infarctions (four left hemisphere, two right hemisphere), and one had a brainstem infarct. In one case, the onset was ipsilateral to a right thalamic infarct. All but one case resolved over 1 to 24 hours, with no lasting sequelae; one patient (the index case) died of cardiac complications 2 weeks after her stroke. 6 If the clinical manifestations were mild, angioedema remained unilateral; if edema was severe, involvement ultimately became bilateral.
Patients who developed angioedema were treated empirically with histamine antagonists (ranitidine and diphenhydramine) and corticosteroids. Racemic epinephrine was not used for fear of inducing intracerebral hemorrhage. Two patients had severe lingual and oropharyngeal swelling, prompting early consultation with an anesthetist, but neither required intubation. Six patients had milder involvement of the tongue and lips; one of these patients had involvement of the lips but not the tongue.
Among nine patients who developed angioedema, five patients were on both an ACEi and a ␤-blocker, two were on a ␤-blocker but not an ACEi, and two were on an ACEi but not a ␤-blocker. The RR of developing angioedema was 13.6 (95% CI 3.0 to 62.7) if the patient was taking an ACEi (table 2). The ACEi implicated included lisinopril (n ϭ 4), cilazapril (n ϭ 1), enalapril (n ϭ 1), and ramipril (n ϭ 1).
Analysis of the ASPECTS scores suggested that the involvement of the insula, M1, or M4 regions (anterior frontal cortex) was associated with the development of angioedema (see table 2 ). If any of those three regions, alone or in combination, showed early signs of ischemia, the RR of developing angioedema was 6.4 (95% CI 1.4 to 30.0).
The side of ischemia was not predictive of angioedema. Five patients with left, three with right hemisphere, and one with brainstem ischemia developed angioedema. No other factors were associated with the development of angioedema in univariable analysis.
Discussion.
We observed an incidence of 5.1% of orolingual angioedema after treatment of acute ischemic stroke with alteplase; most cases were mild. The occurrence of angioedema was strongly related to the use of ACEi (RR 13.6) and to early signs of infarction involving the insular ribbon and frontal cortex anterior to the sylvian fissure (RR 6.4).
ACEi therapy is well known to be associated with the development of spontaneous orolingual angioedema and less commonly at other anatomic sites such as the gut. Bradykinin, the likely effector molecule, is degraded by three zinc metalloproteinases: kininase I enzymes (a family of carboxypeptidases), kininase II enzymes (e.g., ACE), and aminopeptidase P (APP). Kininase I enzymes are a minor pathway in degradation unless ACE is inhibited. Kininase I enzymes degrade bradykinin to des-Arg 9 -bradykinin, which has vasodilatory activity. Variations in expression or activity of APP or kininase I enzymes are additional cofactors necessary to incite the reaction. Therefore, the phenotype of angioedema might only be expressed if both kininase II enzymes are inhibited (by an ACEi) and a hereditary reduction in activity or absence of APP or kininase I occurs. 10 TPA, a serine protease, hydrolyzes plasminogen to plasmin, which cleaves high-molecular-weight kininogen, leading to the formation of bradykinin. Thus, both increased production of bradykinin due to alteplase and decreased breakdown of bradykinin due to the presence of ACE inhibition could lead to angioedema. Changes in autonomic control, lateralized due to the stroke, likely account for the hemilingual onset of this reaction. Analogous to "wrong-way eyes" with thalamic infarction, it was intriguing to observe an incidence of "wrong-way tongue" in a single case of thalamic infarction.
The apparent high rate of angioedema at our institution is probably because we specifically examined for it. Only three patients (1.7%) had severe reactions that were immediately recognizable by the nursing staff and required urgent medical reassessment. This incidence should be confirmed in a second carefully monitored group of stroke patients treated with alteplase.
